Medicinal cannabis manufacturer and seller, Cann Group (ASX:CAN), has secured manufacturing licences from the Federal Department of Health’s Office of Drug Control for its existing Northern and Southern medicinal cannabis facilities in Melbourne.
The licences relate to the manufacturing, packaging, storage, transport and disposal of medicinal cannabis in final dose and intermediate forms.
Appropriate permits will be required in relation to the undertaking of specific activities under the licences.
Cann Group says it now holds all cultivation, production and manufacture licences required under the Narcotics Drugs Act, along with import and export licences required under the Customs Act.
Shares in Cann Group (ASX:CAN) closed 1.38 per cent higher at $2.20 yesterday.